Reneo Pharmaceuticals Inc (RPHM)
2.28
-0.03 (-1.30%)
USD |
NASDAQ |
Jun 24, 16:00
2.28
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 55.77M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -75.91% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.4121 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
05/18 07:31
MT Newswires
03/24 09:19
Globe Newswire
02/02 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/11/2022* | -- | Results | Q2 2022 | -- | -0.59 | -- | |
| 05/10/2022 | -- | Results | Q1 2022 | -0.53 | -0.51 | -3.92% | |
| 03/23/2022 | -- | Results | Q4 2021 | -0.37 | -0.57 | 35.54% | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.52 | -0.42 | -23.81% | |
| 08/11/2021 | -- | Results | Q2 2021 | -0.43 | -0.38 | -14.16% | |
| 05/20/2021 | -- | Results | Q1 2021 | -3.48 | -0.42 | -728.6% |
*Estimated Date/Time
Earnings
Profile
Edit
| Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. |
| URL | https://www.reneopharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Aug. 11, 2022 (est.) |
| Last Earnings Release | May. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 23, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 45.62M |
| Net Income (TTM) | -45.59M |
| Total Assets (Quarterly) | 144.41M |
| Total Liabilities (Quarterly) | 9.094M |
| Shareholders Equity (Quarterly) | 135.32M |
| Cash from Operations (TTM) | -38.39M |
| Cash from Investing (TTM) | -17.92M |
| Cash from Financing (TTM) | 86.19M |
Ratings
Profile
Edit
| Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. |
| URL | https://www.reneopharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Aug. 11, 2022 (est.) |
| Last Earnings Release | May. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| RPHM Tweets |